404 related articles for article (PubMed ID: 17302567)
21. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
Kawabe K; Yoshida M; Homma Y;
BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
[TBL] [Abstract][Full Text] [Related]
22. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia.
Ichioka K; Ohara H; Terada N; Matsui Y; Yoshimura K; Terai A; Arai Y
Int J Urol; 2004 Oct; 11(10):870-5. PubMed ID: 15479292
[TBL] [Abstract][Full Text] [Related]
23. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
24. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Roehrborn CG; Siegel RL
Urology; 1996 Sep; 48(3):406-15. PubMed ID: 8804494
[TBL] [Abstract][Full Text] [Related]
26. Extended-release doxazosin for treatment of renal transplant recipients with benign prostatic hyperplasia.
Zhang Y; Wang Y; Zhang P; Zhang XD; Yang Y
Transplant Proc; 2009 Nov; 41(9):3747-51. PubMed ID: 19917379
[TBL] [Abstract][Full Text] [Related]
27. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia.
Ng CF; Wong A; Cheng CW; Chan ES; Wong HM; Hou SM
J Urol; 2008 Sep; 180(3):1042-6. PubMed ID: 18639296
[TBL] [Abstract][Full Text] [Related]
28. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
Andersen M; Dahlstrand C; Høye K
Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of the doxazosin gastrointestinal therapeutic system for the treatment of benign prostate hyperplasia.
Sun GH; Tsui KH; Wu TT; Chang CH; Cheng CL; Schou M
Kaohsiung J Med Sci; 2010 Oct; 26(10):532-9. PubMed ID: 20950778
[TBL] [Abstract][Full Text] [Related]
30. Controlled-release doxazosin in the treatment of benign prostatic hyperplasia.
Hernandez C; Duran R; Jara J; Castaño I; Moralejo M
Prostate Cancer Prostatic Dis; 2005; 8(4):375-80. PubMed ID: 16264771
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
[TBL] [Abstract][Full Text] [Related]
32. Assessment of patient-reported outcome of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and treated with tamsulosin HCl in Korea.
Chang HS; Park CH; Kim DK; Park JK; Hong SJ; Chung BH; Lee JG; Kim CS; Lee KS; Kim JC
Urology; 2010 May; 75(5):1156-61. PubMed ID: 19914692
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.
Kirby RS
BJU Int; 2003 Jan; 91(1):41-4. PubMed ID: 12614248
[TBL] [Abstract][Full Text] [Related]
34. [Clinical effectiveness and safety of combined therapy with an alpha-blocker and an anticholinergic drug for patients with benign prostatic hyperplasia].
Xiao H; Li HZ; Huang ZM; Li YQ
Zhonghua Wai Ke Za Zhi; 2010 Dec; 48(23):1771-3. PubMed ID: 21211380
[TBL] [Abstract][Full Text] [Related]
35. Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis.
Kirby RS; Quinn S; Mallen S; Jensen D
Int J Clin Pract; 2004 Jan; 58(1):6-10. PubMed ID: 14994963
[TBL] [Abstract][Full Text] [Related]
36. [Doxazosin treatment of disorders of the voiding phase in benign prostatic hyperplasia].
Esteban Fuertes M; Salinas Casado J; Virseda Chamorro M; Ramírez Fernández JC; Salomon Moh'd S; Luengo Alpuente S; Resel Estévez L
Arch Esp Urol; 1997 Dec; 50(10):1057-66. PubMed ID: 9494194
[TBL] [Abstract][Full Text] [Related]
37. A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
Dutkiewicz S
Mater Med Pol; 1995; 27(4):151-2. PubMed ID: 9000839
[TBL] [Abstract][Full Text] [Related]
38. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
Lopatkin NA; Loran OB; Pushkar' DIu; Perepanova TS; Tevlin KP
Urol Nefrol (Mosk); 1998; (3):3-5. PubMed ID: 9644978
[TBL] [Abstract][Full Text] [Related]
39. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
[TBL] [Abstract][Full Text] [Related]
40. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]